i too am very positive on Medlab, but yeah i agree, cash burn is pretty bad lately. probably next quarter isn't too bad as they'll be in the middle of trials 2 and 3, so a little less expense. With $9m in the bank and $1.5m loans available, they maybe have 3 quarters until a CR and that would be pushing it close (unless revenue gets up to the $3m mark consistently).
One thing i hate is mis-trust, and MDC have been very good. but this in the quarterly annoyed me. i get being optimistic/bending the truth, but seriously? using cash outflow from a quarter with a $2.1m R&D return? at least they could've averaged the last 4 quarters ($2.996m) i.e., 3.77 quarters and until $0, so maximum 3 quarters?
anyway, as with a lot of biotech's they will keep struggling for money unless people start speculating on their success to give them another good CR, (like 2018). i don't think they have the ability to do a big CR, because the smaller amount of costs involved in the p3 trials probably don't justify it. only speculation can, which is where they justify it being for p3 fast-tracked, and 'early commercialisation'. imo we'll see another small CR Probably around august timing with US when the before the market starts bidding the share price up.
